Back
Mineralys Therapeutics, Inc. 10K Form
Sell
39
MLYS
Mineralys Therapeutics, Inc.
Last Price:
$36.85
Seasonality Move:
41.51%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MLYS News And Ratings
See the #1 stock for the next 7 days that we like better than MLYS
MLYS Financial Statistics
Sales & Book Value
| Annual Sales: | $0 |
|---|---|
| Cash Flow: | $-28.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $7.30 |
| Price / Book: | 5.06 |
Profitability
| EPS (TTM): | -2.95810 |
|---|---|
| Net Income (TTM): | $-171.4M |
| Gross Margin: | $-43K |
| Return on Equity: | -51.62% |
| Return on Assets: | -48.55% |
Mineralys Therapeutics, Inc. Earnings Forecast
Key Mineralys Therapeutics, Inc. Financial Ratios
-
Per Share Earnings over the last 5 years have been positive in 0 years.
Mineralys Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | MLYS |
| Website: | mineralystx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 25.5 |
| Quick Ratio: | 25.24 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
MLYS Technical Analysis vs Fundamental Analysis
Sell
39
Mineralys Therapeutics, Inc. (MLYS)
is a Sell
Is Mineralys Therapeutics, Inc. a Buy or a Sell?
-
Mineralys Therapeutics, Inc. stock is rated a SellThe current Mineralys Therapeutics, Inc. [MLYS] share price is $36.83. The Score for MLYS is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.